Amgen’s Growth Story Relies Mainly On Continuing Plot Lines

Forecasts Mid-Single-Digit Revenue CAGR Through 2030

Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.

Top view of vintage typewriter with books and copy space
Amgen is writing a growth story built on Repatha, Otezla, biosimilars and new launches • Source: Alamy

Amgen, Inc. executives told investors the story of how it grew to a biopharmaceutical company with 25 commercial brands across 100 global markets during an 8 February business review, and laid out how it plans to write the next chapters of its growth.

Including 2022, in which it expects revenue to total $25.4bn to $26.5bn versus $26bn in 2021, the company said it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip